比较分析已获 FDA 批准的药物在人肺细胞中抗 SARS-CoV-2 的疗效。
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
机构信息
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.
CEO Office, Institut Pasteur Korea, Seongnam, Korea.
出版信息
J Med Virol. 2021 Mar;93(3):1403-1408. doi: 10.1002/jmv.26397. Epub 2020 Aug 16.
Abstract
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC = 0.0022 µM).
摘要
药物重定位是控制当前 COVID-19 大流行的有效方法。此前，我们在 Vero 细胞中鉴定出 24 种对严重急性呼吸综合征冠状病毒 2 具有显著抗病毒作用的 FDA 批准药物。由于抗病毒功效在不同细胞系中可能发生变化，因此我们开发了一种使用人肺细胞的抗病毒筛选测定法，比 Vero 细胞更合适。抗病毒活性的比较分析表明，那法莫司他是在人肺细胞中最有效的药物（IC = 0.0022 µM）。
相似文献
1
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.比较分析已获 FDA 批准的药物在人肺细胞中抗 SARS-CoV-2 的疗效。
J Med Virol. 2021 Mar;93(3):1403-1408. doi: 10.1002/jmv.26397. Epub 2020 Aug 16.
2
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.联合抑制宿主进入因子 PIKfyve 激酶和 TMPRSS2 蛋白酶对 SARS-CoV-2 感染的协同阻断。
J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18.
3
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.发现经美国食品和药物管理局批准的药物贝沙罗汀、西替利司他、二碘羟喹啉和阿比特龙可作为有强大双层筛选系统的潜在 COVID-19 治疗药物。
Pharmacol Res. 2020 Sep;159:104960. doi: 10.1016/j.phrs.2020.104960. Epub 2020 May 28.
4
iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.iPSC 筛选用于药物再利用鉴定了调节宿主细胞易感性的抗 RNA 病毒药物。
FEBS Open Bio. 2021 May;11(5):1452-1464. doi: 10.1002/2211-5463.13153. Epub 2021 Apr 6.
5
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.氯丙嗪抑制 SARS-CoV-2 在人细胞中的复制。
Int J Antimicrob Agents. 2021 Mar;57(3):106274. doi: 10.1016/j.ijantimicag.2020.106274. Epub 2020 Dec 30.
6
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.具有体外抗病毒活性和免疫调节作用的半胱胺有可能成为治疗 COVID-19 的重新定位药物候选物。
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
7
Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.运用计算机模拟和体外实验方法鉴定和重新利用抗严重急性呼吸综合征冠状病毒2的抗病毒药物。
Biochem Biophys Res Commun. 2021 Jan 29;538:137-144. doi: 10.1016/j.bbrc.2020.10.094. Epub 2020 Nov 20.
8
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.采用数据驱动方法和 SARS-CoV-2 进入肺类器官模型鉴定具有针对 COVID-19 的多模态特性的 FDA 批准药物。
Mol Med. 2021 Sep 9;27(1):105. doi: 10.1186/s10020-021-00356-6.
9
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.SARS-CoV-2 感染的形态细胞分析鉴定了用于 COVID-19 的药物再利用候选物。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2105815118.
10
Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.重新利用 FDA 批准药物的筛选结果发现了 29 种 SARS-CoV-2 抑制剂。
J Microbiol Biotechnol. 2020 Dec 28;30(12):1843-1853. doi: 10.4014/jmb.2009.09009.
引用本文的文献
1
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants.从N-0385到N-0920：揭示一种对流行的SARS-CoV-2变体具有皮摩尔抗病毒效力的宿主导向蛋白酶抑制剂。
J Med Chem. 2025 Apr 10;68(7):7119-7136. doi: 10.1021/acs.jmedchem.4c02468. Epub 2025 Mar 31.
2
PBPK-led assessment of antimalarial drugs as candidates for Covid-19: Simulating concentrations at the site of action to inform repurposing strategies.基于 PBPK 的抗疟药物评估作为新冠候选药物：模拟作用部位浓度以提供药物再利用策略信息。
Clin Transl Sci. 2024 Jul;17(7):e13865. doi: 10.1111/cts.13865.
3
Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart.用于鉴定治疗 SARS-CoV-2 感染心脏的抗病毒靶点的模糊优化。
BMC Bioinformatics. 2023 Sep 27;24(1):364. doi: 10.1186/s12859-023-05487-7.
4
Cell-specific genome-scale metabolic modeling of SARS-CoV-2-infected lung to identify antiviral enzymes.基于 SARS-CoV-2 感染肺的细胞特异性全基因组代谢建模来鉴定抗病毒酶。
FEBS Open Bio. 2023 Dec;13(12):2172-2186. doi: 10.1002/2211-5463.13710. Epub 2023 Sep 30.
5
Studying Dynamical Characteristics of Oxygen Saturation Variability Signals Using Haar Wavelet.基于哈尔小波研究血氧饱和度变化信号的动态特征
Healthcare (Basel). 2023 Aug 13;11(16):2280. doi: 10.3390/healthcare11162280.
6
Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections.从市售的已获批准片剂中提取氯硝柳胺，并将其制成水性缓冲溶液，可制备出可能获得批准的用于对抗COVID-19和其他呼吸道感染的口服和鼻喷雾剂。
AAPS Open. 2023;9(1):9. doi: 10.1186/s41120-023-00072-x. Epub 2023 Apr 14.
7
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.FDA 批准的具有抗 SARS-CoV-2 活性的抗病毒药物：从基于结构的再利用到宿主特异性机制。
Biomed Pharmacother. 2023 Jun;162:114614. doi: 10.1016/j.biopha.2023.114614. Epub 2023 Mar 28.
8
Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2.发现 2-氨基喹啉酸衍生物作为强效 SARS-CoV-2 抑制剂。
Bioorg Med Chem Lett. 2023 Apr 1;85:129214. doi: 10.1016/j.bmcl.2023.129214. Epub 2023 Mar 2.
9
Glycogen Synthase Kinase-3 Interaction Domain Enhances Phosphorylation of SARS-CoV-2 Nucleocapsid Protein.糖原合成酶激酶-3 相互作用结构域增强了 SARS-CoV-2 核衣壳蛋白的磷酸化。
Mol Cells. 2022 Dec 31;45(12):911-922. doi: 10.14348/molcells.2022.0130. Epub 2022 Dec 19.
10
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.基于蛋白质结构的计算机辅助药物发现方法：针对 COVID-19 治疗的指导。
Mol Aspects Med. 2023 Jun;91:101151. doi: 10.1016/j.mam.2022.101151. Epub 2022 Oct 28.
本文引用的文献
1
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.瑞德西韦在人肺细胞和表达 SARS-CoV-2 聚合酶的嵌合 SARS-CoV 小鼠中抑制 SARS-CoV-2。
Cell Rep. 2020 Jul 21;32(3):107940. doi: 10.1016/j.celrep.2020.107940. Epub 2020 Jul 7.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
4
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.三例 COVID-19 肺炎老年患者需要氧疗时使用那屈肝素的治疗案例。
Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.从 FDA 批准药物中鉴定抗 SARS-CoV-2 的抗病毒候选药物。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00819-20.
7
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.高剂量与低剂量磷酸氯喹作为辅助治疗对住院的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的影响：一项随机临床试验。
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
8
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.2019冠状病毒病患者的肺栓塞：对患病率增加的认识
Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24.
9
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
10
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
Zotero 插件